Outlook Therapeutics names Kevin Lundquist as CFO ahead of U.S. launch

Outlook Therapeutics, Inc. (Nasdaq: OTLK) has appointed Kevin Lundquist as Chief Financial Officer, effective September 1, 2026, as the biopharmaceutical company prepares for the U.S. commercial launch of its FDA-approved drug LYTENAVA (bevacizumab-vikg).

Lundquist brings more than 20 years of corporate finance and capital markets experience across the pharmaceutical, biotechnology, medical technology, and manufacturing industries. He most recently served as CFO of CapsoVision, Inc., a commercial-stage medical technology company, where he led the company through its 2025 IPO process and oversaw finance, operations, SEC reporting, and capital raises.

Prior to CapsoVision, Lundquist was CFO of Abzena Biologics, a private equity-backed contract development and manufacturing organization. He also served as Vice President of Finance at Revance Therapeutics, and earlier held the role of Global Head of Finance for Genentech/Roche's Drug Substance Biologics Operations. He served as CFO of Caterpillar's Japan division, which oversaw a $6 billion annual-revenue business, and held finance positions at Abbott Laboratories. He holds an M.B.A. from Utah State University and a B.S. from the University of Utah.

Concurrent with Lundquist's appointment, Lawrence Kenyon will step down as CFO on September 1, 2026, and will remain with the company as a non-executive employee through September 30, 2026.

As part of his compensation, Outlook Therapeutics' Board of Directors approved an inducement grant of options to purchase 500,000 shares of common stock. The options will be issued September 1, 2026, priced at the closing stock price on that date, and will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments over the following three years.

LYTENAVA is indicated for the treatment of neovascular (wet) age-related macular degeneration and holds FDA approval in the U.S., as well as marketing authorizations from the European Commission and the UK's MHRA.

You May Also Be Interested In

• Polaryx Therapeutics names Will Charlton as chief medical officer
• California Resources completes $63M acquisition of Crimson Midstream
• Hyperscale Data ends Bitcoin mining to prep Michigan AI data center